Rachael Watson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rachael Watson has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Barry J. Byrne
University of Florida
1 shared publication - Darin J. Falk
Pediatrics, University of Florida, Gainesville, FL
1 shared publication - Hung-Chuan Chiu
Institute of Molecular Biology, National Chung Hsing University, Taichung, 402, Taiwan
1 shared publication - Kirsten E. Coleman
Powell Gene Therapy Center, University of Florida, Gainesville
1 shared publication - Marda Jorgensen
University of Florida
1 shared publication - Mark Potter
Powell Gene Therapy Center Vector Core, University of Florida, Gainesville, FL 32610, USA
1 shared publication
Latest Publications
- Open Access
- 18 June 2012
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 10 (1) , 3
An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery
The appropriate tropism of adeno-associated virus (AAV) vectors that are systemically injected is crucial for successful gene therapy when local injection is not practical. Acidic oligopeptides have been shown to enhance drug delivery to bones. In this study six-L aspartic acids (D6) were inserted into the AAV2 capsid protein sequence between amino acid residues 587 and 588. 129SVE mice were injected with double-stranded wild-type- (WT-) or D6-AAV2 mCherry expression vectors (3.24 x 1010 vg per animal) via the superficial temporal vein within 24 hours of birth. Fluorescence microscopy and quantitative polymerase chain reaction confirmed higher levels of mCherry expression in the paraspinal and gluteus muscles in the D6-AAV2 injected mice. The results revealed that although D6-AAV2 was less efficient in the transduction of immortalized cells stronger mCherry signals were detected over the spine and pelvis by live imaging in the D6-AAV2-injected mice than were detected in the WT-AAV2-injected mice. In addition, D6-AAV2 lost the liver tropism observed for WT-AAV2. An acidic oligopeptide displayed on AAV2 improves axial muscle tropism and decreases liver tropism after systemic delivery. This modification should be useful in creating AAV vectors that are suitable for gene therapy for diseases involving the proximal muscles.
- 18 June 2012
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 10 (1) , 3
Open AccessAn acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery
The appropriate tropism of adeno-associated virus (AAV) vectors that are systemically injected is crucial for successful gene therapy when local injection is not practical. Acidic oligopeptides have been shown to enhance drug delivery to bones. In this study six-L aspartic acids (D6) were inserted into the AAV2 capsid protein sequence between amino acid residues 587 and 588. 129SVE mice were injected with double-stranded wild-type- (WT-) or D6-AAV2 mCherry expression vectors (3.24 x 1010 vg per animal) via the superficial temporal vein within 24 hours of birth. Fluorescence microscopy and quantitative polymerase chain reaction confirmed higher levels of mCherry expression in the paraspinal and gluteus muscles in the D6-AAV2 injected mice. The results revealed that although D6-AAV2 was less efficient in the transduction of immortalized cells stronger mCherry signals were detected over the spine and pelvis by live imaging in the D6-AAV2-injected mice than were detected in the WT-AAV2-injected mice. In addition, D6-AAV2 lost the liver tropism observed for WT-AAV2. An acidic oligopeptide displayed on AAV2 improves axial muscle tropism and decreases liver tropism after systemic delivery. This modification should be useful in creating AAV vectors that are suitable for gene therapy for diseases involving the proximal muscles.